Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd
Nearly half of patients dosed with Merck and Daiichi Sankyo’s ifinatamab deruxtecan responded to the treatment, helping the partners mount...
Merck
Nearly half of patients dosed with Merck and Daiichi Sankyo’s ifinatamab deruxtecan responded to the treatment, helping the partners mount...
